HCP0910

DRUG2 trials

Sponsors

Hanmi Pharmaceutical Company Limited

Conditions

AsthmaChronic Obstructive Pulmonary Disease

Phase 1

Therapeutic Equivalence Study of HCP0910 250/50 Mcg to Seretide 250 Diskus in Asthmatic Patients

CompletedNCT01521455

Hanmi Pharmaceutical Company LimitedAsthma

Start: 2012-02-29End: 2013-07-31Updated: 2013-08-23

Phase 3

Clinical Efficacy and Safety Evaluation of HCP1202 in COPD Patients

Hanmi Pharmaceutical Company LimitedChronic Obstructive Pulmonary Disease

Start: 2016-10-31End: 2018-04-30Target: 252Updated: 2016-10-21